# Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer

> **NCT00010322** · PHASE3 · TERMINATED · sponsor: **Intarcia Therapeutics**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** atamestane
- **DRUG:** toremifene

## Key facts

- **NCT ID:** NCT00010322
- **Lead sponsor:** Intarcia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-10
- **Primary completion:** 2001-05
- **Final completion:** 2001-05
- **Target enrollment:** — (—)
- **Why stopped:** Withdrawn due to change in standard of care - new protocol required
- **Last updated:** 2014-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00010322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00010322, "Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00010322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*